LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Kodu・Aktsiate loetelu・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Suletud

SektorTervishoid

25.93 4.05

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.21

Max

27.03

Põhinäitajad
By Trading Economics
Sissetulek	51M -129M
Müük	207M
Kasumimarginaal	-62.319
Töötajad	1,371
EBITDA	8.8M -105M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+111.85% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	460M 2.4B
Eelmine avamishind	21.88
Eelmine sulgemishind	25.93

Uudiste sentiment

By Acuity

40%

60%

154 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

32.76 / 39.24 Toetus ja vastupanu

Ultragenyx Pharmaceutical Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. mai 2026, 23:41 UTC

Tulu

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. mai 2026, 21:40 UTC

Tulu

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. mai 2026, 23:12 UTC

Tulu

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. mai 2026, 23:11 UTC

Tulu

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:07 UTC

Tulu

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. mai 2026, 23:05 UTC

Tulu

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. mai 2026, 23:04 UTC

Tulu

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. mai 2026, 22:50 UTC

Tulu

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. mai 2026, 21:58 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:47 UTC

Market Talk

Tulu

Costco Posts 13% Sales Growth in April -- Market Talk

6. mai 2026, 21:46 UTC

Tulu

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. mai 2026, 21:40 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. mai 2026, 21:32 UTC

Kuumad aktsiad

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. mai 2026, 21:29 UTC

Tulu

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Ultragenyx Pharmaceutical Inc Prognoos

Hinnasiht

By TipRanks

111.85% tõus

12 kuu keskmine prognoos

Keskmine 52.56 USD 111.85%

Kõrge 84 USD

Madal 25 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Ultragenyx Pharmaceutical Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

Osta

Hoia

Müü

Põhineb 18 analüütiku instrumendi Ultragenyx Pharmaceutical Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

32.76 / 39.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

154 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.